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Depending on the mechanisms by which cancer develops
and the strategies tumors use to escape the immune
system, cancer therapies are more or less successful. A
combination of different therapeutic agents, such as den-
dritic cell (DC) vaccines loaded with tumor antigens and
adoptive transfer of tumor-specific T-cells, may enhance
the chances of effective cures. Thus, for the isolation of T-
cell receptors (TCR) that can be transferred into patient-
derived lymphocytes, enabling T-cells to recognize
and eliminate tumor cells, we induced tumor-associated-
antigen (TAA)-specific T-cells by loading DC with in vitro
transcribed (ivt) RNA coding for 5 different cancer-testis-
antigens (CTA, GAGE-1, MAGE-A4, NY-ESO-1, SSX4
and XAGE-1). As CTA are self-antigens with a limited
expression in immune privileged tissues and in various
tumor entities, we needed to bypass negative selection of
highly avid T-cells specific for CTA restricted by self-
MHC molecules. Therefore, allo-reactive T-cells, which
are able to recognize antigens on foreign MHC molecules,
offer the possibility to gain high-affinity TCR. Using DC
and responding PBL from two donors that expressed dif-
ferent MHC allotypes resulted in the presentation of CTA
on several different MHC molecules encoded by endogen-
ous HLA genes. In addition, taking into account that CD4
+ T cell help is considered to be essential for the activation
and expansion of antigen-specific CD8+ T-cells, target
antigens were fused to cell internal localization signals
(targeting) which led to presentation by both MHC-I and
-II molecules of antigen-presenting cells, allowing the
simultaneous activation of CD4+ and CD8+ T-cells. By
this means, several CTA-specific T-cell clones were identi-
fied. Furthermore, we were able to demonstrate a clear
benefit of using DC transfected with targeting-linked
Melan-A-ivt-mRNA compared with DC transfected with
standard Melan-A-ivt-mRNA in a humanized in vivo DC
vaccination model. NOD/scid IL2Rgnull (NSG) mice are
deficient for T-, B- and NK-cells, providing a niche for
engraftment of human peripheral blood mononuclear cells
(PBMC). Vaccination of reconstituted mice with DC
loaded either with targeting-Melan-A-ivt-mRNA or with
Melan-A-ivt-mRNA resulted in a superior induction-
capacity of targeting-Melan-A-ivt-mRNA-transfected DC,
demonstrated by significantly greater activation and prolif-
eration of Melan-A-specific CD8+ T-cells. In conclusion,
we were able to induce tumor-antigen specific CD8+
T-cells in vitro and in vivo by using targeting-linked anti-
gens provided to DC. Since adoptive T-cell transfer and
DC vaccination hitherto have failed to be optimally effica-
cious in clinical trials, the combination of these two
approaches may provide greater clinical benefit to more
patients.
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